Update shared on 27 Oct 2025
Fair value Increased 1.92%Analysts have raised their price target for JD Health International from approximately ¥68.78 to ¥70.10. This reflects slight improvements in expected revenue growth, profit margin, and valuation metrics.
What's in the News
- Mr. Enlin Jin has resigned as CEO of JD Health International, effective September 29, 2025, to focus on family. Mr. Dong Cao, who has a long tenure within JD Group and experience as CFO, will take over as CEO on the same date (Key Developments).
- JD Health International held a Board Meeting on August 14, 2025, to review and approve the unaudited interim results for the first half of 2025 and to consider a recommendation for the payment of an interim dividend (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly from HK$68.78 to HK$70.10.
- Discount Rate remains unchanged at 6.89%.
- Revenue Growth has increased marginally from 14.79% to 14.90%.
- Net Profit Margin shows a very modest increase, moving from 7.06% to 7.06%.
- Future P/E Ratio has edged up slightly from 35.52x to 36.01x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.